Total raised
$65.5M
Last: Series C 2020-02
Stage
Series C
Founded
2015
Headcount
15
HQ
Rehovot
Sector
Health Tech & Life Sciences
About
NeoTX is leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies. STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The technology effectively converts a weak immune response against the tumor to a powerful yet safe native antibacterial immune reaction. The company's lead STR molecule, Naptumomab estafenatox, is currently in clinical development for advanced solid tumors.
Funding history · 3 rounds · $65.5M total
2020-02
Series C
$45.0M
2017-12
Series B
$8.8M
2016-10
Series A
$9.2M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
drug-developmentdrug-discoverybiopharmaceuticalcancer-therapyoncologycancertherapeuticsimmunotherapycell-therapypharmaceuticals